Revel Pharmaceuticals is focused on developing innovative therapeutic solutions that address the fundamental causes of aging and chronic diseases. The company emphasizes the role of toxic protein accumulation and metabolites in the onset of various diseases. Their approach involves creating therapies that not only repair the damage caused by these toxic substances but also aim to reverse the progression of the diseases associated with aging. This strategy highlights their commitment to tackling the underlying drivers of both aging and chronic illness, positioning them at the forefront of biopharmaceutical advancements.

In addition to their core focus on reversing age-related damage and clearing toxic metabolites, Revel Pharmaceuticals is also dedicated to repairing autoimmunity. This multifaceted approach suggests a comprehensive understanding of the complex interactions between aging, disease, and the immune system. By targeting these critical areas, Revel aims to develop effective treatments that can significantly improve health outcomes for individuals suffering from age-related conditions and chronic diseases, ultimately enhancing the quality of life as people age.

United States

Revel Pharmaceuticals is a biotechnology commercializing therapeutic enzymes to degrade age associated molecule damage. We are targeting pathological age associated compounds known as Advanced Glycation End Products (AGEs) which build up on long lived proteins like collagen. AGE accumulation is implicated in multiple diseases of aging, thus Revel Pharmaceuticals is strategically position to develop therapeutics across multiple indications.

Revel Pharmaceuticals

Company Details